- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,250 | 24.06.24 09:16:03 | +0,860 | +0,98% | 88,130 | 88,180 | 87,820 | 87,390 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 984,600 | 24.06.24 08:12:32 | -3,000 | -0,30% | 988,200 | 990,800 | 984,600 | 987,600 |
